> Fourth-quarter revenue : €106.4M, +4.3% at constant exchange rates
> Annual profitability target confirmed
VILLEPINTE, France, Feb. 10, 2015 (GLOBE NEWSWIRE) -- Guerbet (FR0000032526 GBT), a global specialist in contrast agents for medical imaging, is publishing annual revenue for 2014 of €409.0M, representing a 4.9% increase. Excluding exchange rate effects, the annual revenue stands at €411.6M, growing by 5.6%, in line with the guidance.
Consolidated (IFRS) revenue at 31 December
| In millions of Euros | 2014 | 2013 | Change (%) |
| First-quarter | 96.6 | 91.0 | 6.1% |
| Second-quarter | 106.1 | 101.4 | 4.6% |
| Third-quarter | 99.9 | 96.0 | 4.0% |
| Fourth-quarter | 106.4 | 101.3 | 5.1% |
| Total | 409.0 | 389.7 | 4.9% |
| Of which Europe | 289.3 | 274.5 | 5.4% |
| Of which Other Markets | 119.7 | 115.2 | 3.9% |
Contribution to growth from all the geographies in the fourth quarter
Fourth-quarter revenue totals €106.4M, rising by 5.1% (+4.3% at constant exchange rates). Sales in Europe (+6.3%) and in Other Markets (+2.3%) were driven particularly by the MRI segment (+10.1%) and especially by Dotarem ® in the US.
The 4 business segments grew in 2014
Full-year sales in the MRI segment (€168.3M in 2014) were strong. Despite the adverse effect of an inventory build-up in Germany, the level of activity was 3.0% higher. Dotarem ® was also rolled out in the US with strong year-end sales growth and a broadening of the customer base.
In the X-Ray segment (€187.9M in 2014), revenue rose slightly versus 2013 (+1.1%), thanks particularly to sales of Xenetix ® . The new ScanBag ® by Xenetix filling line in Aulnay should reach its expected production rate as of the second half of 2015. This delay will have a one-off impact on this activity's sales and margins in the first half of 2015.
The Group's other growth platforms ( Interventional Radiology, Medical Devices, USA and China ) performed well, as expected, recording 25% growth in 2014. The IRT segment exceeded the target of €30M revenue over the year, while in the Medical Devices segment, the FlowSens ® injector lived up to the success of its commercial launch.
Guerbet confirms its profit guidance, of an operating margin between 9% and 10% (current operating income / reported sales), on the strength of this solid commercial performance.
Upcoming events
- Publication of the 2014 annual results on 12 March 2015 before trading
About Guerbet
Guerbet is a pioneer in the contrast agent field, with more than 80 years' experience, and is the only pharmaceutical group dedicated to medical imaging worldwide. It offers a comprehensive range of X-Ray, Magnetic Resonance Imaging (MRI) and Interventional Radiology and Theranostics (IRT) products, along with a range of injectors and related medical devices to improve the diagnostic and treatment of patients. To discover new products and ensure future growth, Guerbet invests heavily in R&D, spending around 10% of its sales each year. Guerbet (GBT) is listed on NYSE Euronext Paris (Segment B - Mid Caps) and generated revenue of €390 million in 2013. It has a total workforce of 1,485 employees, 1,000 of whom are based in France.
For further information about Guerbet , please go to www.guerbet.com ;
Contacts
| Guerbet | Actifin |
| Jean-François Le Martret Chief Financial Officer 01 45 91 50 00 | Nicolas Meunier/Benjamin Lehari 01 56 88 11 11 nmeunier@actifin.fr/blehari@actifin.fr Press Jennifer Jullia 01 56 88 11 19 jjullia@actifin.fr |
Press release http://hugin.info/159769/R/1893294/670836.pdf
HUG#1893294
